JP2022533570A5 - - Google Patents
Info
- Publication number
- JP2022533570A5 JP2022533570A5 JP2021566480A JP2021566480A JP2022533570A5 JP 2022533570 A5 JP2022533570 A5 JP 2022533570A5 JP 2021566480 A JP2021566480 A JP 2021566480A JP 2021566480 A JP2021566480 A JP 2021566480A JP 2022533570 A5 JP2022533570 A5 JP 2022533570A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- disorder
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024117746A JP2024156729A (ja) | 2019-05-13 | 2024-07-23 | Ｆｇｆｒ阻害剤およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846991P | 2019-05-13 | 2019-05-13 | |
| US62/846,991 | 2019-05-13 | ||
| US202062993957P | 2020-03-24 | 2020-03-24 | |
| US62/993,957 | 2020-03-24 | ||
| US202063011469P | 2020-04-17 | 2020-04-17 | |
| US63/011,469 | 2020-04-17 | ||
| PCT/US2020/032474 WO2020231990A1 (en) | 2019-05-13 | 2020-05-12 | Fgfr inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024117746A Division JP2024156729A (ja) | 2019-05-13 | 2024-07-23 | Ｆｇｆｒ阻害剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533570A JP2022533570A (ja) | 2022-07-25 |
| JP2022533570A5 true JP2022533570A5 (cg-RX-API-DMAC10.html) | 2023-05-19 |
| JP7527309B2 JP7527309B2 (ja) | 2024-08-02 |
Family
ID=73289291
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566480A Active JP7527309B2 (ja) | 2019-05-13 | 2020-05-12 | Ｆｇｆｒ阻害剤およびそれらの使用 |
| JP2024117746A Pending JP2024156729A (ja) | 2019-05-13 | 2024-07-23 | Ｆｇｆｒ阻害剤およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024117746A Pending JP2024156729A (ja) | 2019-05-13 | 2024-07-23 | Ｆｇｆｒ阻害剤およびそれらの使用 |
Country Status (17)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3065954T3 (en) * | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| JP2021017595A (ja) * | 2019-07-18 | 2021-02-15 | 花王株式会社 | アニオン変性セルロース |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| CN115160319B (zh) * | 2021-04-01 | 2023-12-26 | 西安新通药物研究股份有限公司 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
| TW202304889A (zh) * | 2021-04-03 | 2023-02-01 | 大陸商海南耀臻生物醫藥科技有限公司 | 作為fgfr抑制劑的雜環化合物及其應用 |
| WO2023011581A1 (zh) * | 2021-08-04 | 2023-02-09 | 江苏恒瑞医药股份有限公司 | 含氮杂环化合物、其制备方法及其在医药上的应用 |
| CA3231948A1 (en) * | 2021-09-23 | 2023-03-30 | Jingyu Hu | Fgfr inhibitors and methods of use thereof |
| WO2023104035A1 (zh) * | 2021-12-06 | 2023-06-15 | 英矽智能科技(上海)有限公司 | 取代的单环或双环杂环化合物，其制法与医药上的用途 |
| WO2023151560A1 (en) * | 2022-02-08 | 2023-08-17 | Etern Biopharma (Shanghai) Co., Ltd. | Bicyclic heteroaryl compounds and uses thereof |
| US20260152503A1 (en) * | 2022-03-31 | 2026-06-04 | Acerand Therapeutics (Hong Kong) Limited | Spirobicyclic compounds |
| WO2023202625A1 (zh) * | 2022-04-20 | 2023-10-26 | 深圳福沃药业有限公司 | Fgfr2抑制剂及使用方法 |
| US20250313524A1 (en) * | 2022-05-10 | 2025-10-09 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| JP2025523588A (ja) * | 2022-06-29 | 2025-07-23 | インシリコ メディスン アイピー リミテッド | Ｆｇｆｒ２及びｆｇｆｒ３の阻害剤並びにその使用 |
| CN119421872A (zh) * | 2022-06-29 | 2025-02-11 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| CA3266687A1 (en) * | 2022-09-07 | 2024-03-14 | Eli Lilly And Company | PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT |
| CN120051471A (zh) * | 2022-10-18 | 2025-05-27 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| CN115594682B (zh) * | 2022-10-26 | 2024-03-15 | 苏州浦合医药科技有限公司 | Fgfr2抑制剂 |
| WO2024109799A1 (zh) * | 2022-11-22 | 2024-05-30 | 西藏海思科制药有限公司 | 一种嘧啶衍生物及其在医药上的应用 |
| WO2024175121A1 (zh) * | 2023-02-24 | 2024-08-29 | 希格生科（深圳）有限公司 | α，β-不饱和酰胺类化合物及其应用 |
| TW202442224A (zh) * | 2023-03-20 | 2024-11-01 | 香港商英矽智能科技知識產權有限公司 | Fgfr2與fgfr3之抑制劑及其用途 |
| WO2024208315A1 (zh) * | 2023-04-07 | 2024-10-10 | 中国医药研究开发中心有限公司 | 芳香杂环类化合物及其制备方法和医药用途 |
| WO2024245193A1 (zh) * | 2023-05-26 | 2024-12-05 | 上海艾力斯医药科技股份有限公司 | 杂芳环类化合物、其药物组合物及其应用 |
| KR20260009912A (ko) | 2023-06-05 | 2026-01-20 | 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. | 피롤로피리미딘 유도체 및 의약물 제조에서 이의 용도 |
| WO2025067484A1 (en) * | 2023-09-28 | 2025-04-03 | Acerand Therapeutics (Hong Kong) Limited | Crystal forms and salts of spirobicyclic compound |
| CN117343068B (zh) * | 2023-09-28 | 2026-04-28 | 上海相辉医药科技有限公司 | 一种FGFR2抑制剂Lirafugratinib(RLY-4008)的制备方法 |
| KR20260115897A (ko) * | 2023-11-17 | 2026-07-27 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 질소 함유 헤테로아릴 유도체, 이의 제조 방법 및 의약학적 응용 |
| CN120230109A (zh) * | 2023-12-29 | 2025-07-01 | 广州科恩泰生物医药科技有限公司 | 一种亚砜亚胺类化合物的酸式盐的晶型及其制备方法和用途 |
| WO2025149021A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种吡啶并吡咯衍生物及其在医药上的应用 |
| WO2025237312A1 (zh) * | 2024-05-15 | 2025-11-20 | 深圳福沃药业有限公司 | 一类含苯并异噁唑结构的高选择性fgfr2抑制剂及其制备方法和应用 |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026119036A1 (zh) * | 2024-12-04 | 2026-06-11 | 康百达（四川）生物医药科技有限公司 | 一种吡咯并嘧啶衍生物的晶型及其制备方法 |
| CN120136834B (zh) * | 2025-02-13 | 2026-02-03 | 浙江工业大学 | 一种手性吡喃环化合物及其合成方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB119249A (en) | 1917-06-09 | 1918-10-03 | Du Pont | Process of Producing Alcohols. |
| US2319070A (en) | 1938-03-31 | 1943-05-11 | Eastman Kodak Co | Manufacture of unsaturated aliphatic acids and anhydrides |
| ATE202109T1 (de) | 1993-03-12 | 2001-06-15 | Upjohn Co | Kristallines ceftiofur (freie säure) |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| PT938486E (pt) * | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| MX9909255A (en) | 1997-04-09 | 2000-06-01 | Commw Scient Ind Res Org | Process for covalently coupling organic compounds utilizing diboron derivatives for preparation of an aryl boronic acid |
| AUPQ441499A0 (en) | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| GB0031080D0 (en) | 2000-12-20 | 2001-01-31 | Novartis Ag | Organic compounds |
| AUPR548601A0 (en) * | 2001-06-06 | 2001-06-28 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyrazinecompound and pharmaceutical use thereof |
| US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| AU2002333524A1 (en) | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| CN1871240B (zh) | 2003-08-26 | 2012-11-07 | 帝人制药株式会社 | 吡咯并嘧啶酮衍生物 |
| JP2007510136A (ja) | 2003-10-06 | 2007-04-19 | ソルヴィーアス アクチェンゲゼルシャフト | 分子状固体の結晶形態を並行検出する方法 |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| JP2008505084A (ja) | 2004-06-29 | 2008-02-21 | アムゲン インコーポレイティッド | フラノピリミジン |
| MXPA06015237A (es) | 2004-06-29 | 2007-12-10 | Amgen Inc | Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck. |
| DE102005061170A1 (de) * | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| CN102286048A (zh) * | 2011-06-24 | 2011-12-21 | 吉林大学 | 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物 |
| WO2013078254A1 (en) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Bicyclic heteroaryl derivatives as kinase inhibitors |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| AU2013210403B2 (en) * | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| DK3269370T3 (da) * | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| ES3065954T3 (en) | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| CN116947885B (zh) | 2019-09-20 | 2026-01-23 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| EP4053120A4 (en) | 2019-10-28 | 2023-11-01 | Nippon Soda Co., Ltd. | COMPOUND 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| KR102980664B1 (ko) | 2020-04-17 | 2026-06-19 | 신젠타 크롭 프로텍션 아게 | 제초 화합물 |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
-
2020
- 2020-05-12 ES ES23210430T patent/ES3065954T3/es active Active
- 2020-05-12 US US17/595,257 patent/US12522605B2/en active Active
- 2020-05-12 MX MX2021013146A patent/MX428348B/es unknown
- 2020-05-12 JP JP2021566480A patent/JP7527309B2/ja active Active
- 2020-05-12 BR BR112021022457A patent/BR112021022457A2/pt unknown
- 2020-05-12 PH PH1/2021/552862A patent/PH12021552862A1/en unknown
- 2020-05-12 CN CN202411852620.8A patent/CN119874707A/zh active Pending
- 2020-05-12 AU AU2020274083A patent/AU2020274083B9/en active Active
- 2020-05-12 KR KR1020217040628A patent/KR102923990B1/ko active Active
- 2020-05-12 KR KR1020267003072A patent/KR20260030158A/ko active Pending
- 2020-05-12 SG SG11202111327XA patent/SG11202111327XA/en unknown
- 2020-05-12 WO PCT/US2020/032474 patent/WO2020231990A1/en not_active Ceased
- 2020-05-12 CN CN202080035916.4A patent/CN114126620B/zh active Active
- 2020-05-12 PE PE2021001878A patent/PE20220573A1/es unknown
- 2020-05-12 CA CA3137458A patent/CA3137458A1/en active Pending
- 2020-05-12 EP EP23210430.7A patent/EP4306529B1/en active Active
- 2020-05-12 EP EP20805444.5A patent/EP3968999B1/en active Active
- 2020-05-12 IL IL287940A patent/IL287940B2/en unknown
- 2020-05-12 ES ES20805444T patent/ES2974985T3/es active Active
- 2020-05-13 TW TW109115853A patent/TWI855070B/zh active
- 2020-05-13 TW TW113133749A patent/TWI921912B/zh active
-
2021
- 2021-11-03 CL CL2021002882A patent/CL2021002882A1/es unknown
-
2023
- 2023-01-31 US US18/162,127 patent/US11780845B2/en active Active
-
2024
- 2024-07-23 JP JP2024117746A patent/JP2024156729A/ja active Pending
-
2025
- 2025-04-08 AU AU2025202494A patent/AU2025202494A1/en active Pending
- 2025-09-29 IL IL323675A patent/IL323675A/en unknown
- 2025-11-25 US US19/401,237 patent/US20260138983A1/en active Pending